Bio-Thera Solutions begins dosing in Phase I trial of cancer drug
Bio-Thera Solutions has commenced dosing in the Phase I clinical trial of BAT6005, a monoclonal antibody to target TIGIT in cancer patients.
Source: clinicaltrialsarena.com
📰 Engineered Antibody News
Engineered Antibody News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Engineered Antibody. Real-time updates on events, politics, business and more.